Patents by Inventor Ehsan Sarafraz-Yazdi

Ehsan Sarafraz-Yazdi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Small Molecule Cancer Treatments that Cause Necrosis in Cancer Cells But Do Not Affect Normal Cells
    Publication number: 20230364178
    Abstract: A method of treating cancer in a subject, including: providing a subject having a plurality of cancer cells; and administering to the subject, a therapeutically effective amount of a composition including: an HDM-2 binding component; and a membrane resident component, the membrane resident component bound to the HDM-2 binding component. Also provided are a method of selectively necrosing cancer cells, a method of causing membranolysis in cancer cells, and a cancer treatment composition.
    Type: Application
    Filed: September 27, 2022
    Publication date: November 16, 2023
    Inventors: Matthew R. Pincus, Josef Michl, Ehsan Sarafraz-Yazdi
  • HDM-2 TARGETING COMPOSITIONS CAUSE TUMOR CELL NECROSIS RATHER THAN APOPTOSIS OF CANCER CELLS
    Publication number: 20230174601
    Abstract: An aspect of the invention provides a method of selectively necrosing cells, comprising: providing a plurality cells, including at least one cancer cell and at least one non-cancerous cell; and administering to the cells a compound, including an HDM-2 targeting component and a cytotoxic component attached to the HDM-2 targeting component, wherein said compound comprises a membrane-active form.
    Type: Application
    Filed: November 22, 2022
    Publication date: June 8, 2023
    Inventors: Matthew R. Pincus, Josef Michl, Ehsan Sarafraz-Yazdi
  • Small Molecule Cancer Treatments that Cause Necrosis in Cancer Cells But Do Not Affect Normal Cells
    Publication number: 20210205403
    Abstract: A method of treating cancer in a subject, including: providing a subject having a plurality of cancer cells; and administering to the subject, a therapeutically effective amount of a composition including: an HDM-2 binding component; and a membrane resident component, the membrane resident component bound to the HDM-2 binding component. Also provided are a method of selectively necrosing cancer cells, a method of causing membranolysis in cancer cells, and a cancer treatment composition.
    Type: Application
    Filed: March 5, 2021
    Publication date: July 8, 2021
    Inventors: Matthew R. Pincus, Josef Michl, Ehsan Sarafraz-Yazdi
  • SMALL MOLECULE CANCER TREATMENTS THAT CAUSE NECROSIS IN CANCER CELLS BUT DO NOT AFFECT NORMAL CELLS
    Publication number: 20200038471
    Abstract: A method of treating cancer in a subject, including: providing a subject having a plurality of cancer cells; and administering to the subject, a therapeutically effective amount of a composition including: an HDM-2 binding component; and a membrane resident component, the membrane resident component bound to the HDM-2 binding component. Also provided are a method of selectively necrosing cancer cells, a method of causing membranolysis in cancer cells, and a cancer treatment composition.
    Type: Application
    Filed: October 23, 2019
    Publication date: February 6, 2020
    Inventors: Matthew R. Pincus, Josef Michl, Ehsan Sarafraz-Yazdi
  • HDM-2 TARGETING COMPOSITIONS CAUSE TUMOR CELL NECROSIS RATHER THAN APOPTOSIS OF CANCER CELLS
    Publication number: 20200002394
    Abstract: An aspect of the invention provides a method of selectively necrosing cells, comprising: providing a plurality cells, including at least one cancer cell and at least one non-cancerous cell; and administering to the cells a compound, including an HDM-2 targeting component and a cytotoxic component attached to the HDM-2 targeting component, wherein said compound comprises a membrane-active form.
    Type: Application
    Filed: August 30, 2019
    Publication date: January 2, 2020
    Inventors: Matthew R. Pincus, Josef Michl, Ehsan Sarafraz-Yazdi
  • SMALL MOLECULE CANCER TREATMENTS THAT CAUSE NECROSIS IN CANCER CELLS BUT DO NOT AFFECT NORMAL CELLS
    Publication number: 20170209521
    Abstract: A method of treating cancer in a subject, including: providing a subject having a plurality of cancer cells; and administering to the subject, a therapeutically effective amount of a composition including: an HDM-2 binding component; and a membrane resident component, the membrane resident component bound to the HDM-2 binding component. Also provided are a method of selectively necrosing cancer cells, a method of causing membranolysis in cancer cells, and a cancer treatment composition.
    Type: Application
    Filed: December 7, 2016
    Publication date: July 27, 2017
    Inventors: Matthew R. Pincus, Josef Michl, Ehsan Sarafraz-Yazdi
  • Small molecule cancer treatments that cause necrosis in cancer cells but do not affect normal cells
    Patent number: 9539327
    Abstract: A method of treating cancer in a subject, including: providing a subject having a plurality of cancer cells; and administering to the subject, a therapeutically effective amount of a composition including: an HDM-2 binding component; and a membrane resident component, the membrane resident component bound to the HDM-2 binding component. Also provided are a method of selectively necrosing cancer cells, a method of causing membranolysis in cancer cells, and a cancer treatment composition.
    Type: Grant
    Filed: November 26, 2008
    Date of Patent: January 10, 2017
    Assignee: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
    Inventors: Matthew R. Pincus, Josef Michl, Ehsan Sarafraz-Yazdi
  • MEMBRANE RESIDENT PEPTIDE IN ANTI-CANCER PEPTIDES CAUSES TUMOR CELL NECROSIS RATHER THAN APOPTOSIS OF CANCER CELLS
    Publication number: 20140371156
    Abstract: An aspect of the invention provides a method of selectively necrosing cells, comprising: providing a plurality cells, including at least one cancer cell and at least one non-cancerous cell; and administering to the cells a compound, including an HDM-2 targeting component and a cytotoxic component attached to the HDM-2 targeting component, wherein said compound comprises a membrane-active form.
    Type: Application
    Filed: August 27, 2014
    Publication date: December 18, 2014
    Applicant: THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
    Inventors: Matthew R. Pincus, Josef Michl, Ehsan Sarafraz-Yazdi
  • Membrane resident peptide in anti-cancer peptides causes tumor cell necrosis rather than apoptosis of cancer cells
    Patent number: 8822419
    Abstract: An aspect of the invention provides a method of selectively necrosing cells, comprising: providing a plurality cells, including at least one cancer cell and at least one non-cancerous cell; and administering to the cells a compound, including an HDM-2 targeting component and a cytotoxic component attached to the HDM-2 targeting component, wherein said compound comprises a membrane-active form.
    Type: Grant
    Filed: October 2, 2009
    Date of Patent: September 2, 2014
    Assignee: The Research Foundation of State University of New York
    Inventors: Matthew R. Pincus, Josef Michl, Ehsan Sarafraz-Yazdi